All In Biotech

Drug Trial Radar · NCT06798454

Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects and Patients (PBC/PSC)

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 15, 2024

Primary completion

Apr 23, 2025

Study completion Apr 23, 2025

Sponsor

Lead sponsor
Parvus Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Avance Clinical Pty Ltd.
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn what happens to PVT201 when it enters your body and how it affects your immune system. It will also learn about the safety of PVT201 after a single dose. The main questions it aims to answer are: Will participants experience any side effects when taking PVT201? How long does it take PVT201 to leave your body after you take it? Healthy volunteers will: stay in the clinic for two nights, get one dose of PVT201 or a placebo intravenously (through a vein) on Day 1, have blood drawn periodically throughout their stay and be monitored for side effects, and return to the clinic approximately one week after their dose for a final study visit. Patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) will have the same procedures performed as healthy volunteers; however, none of the patients will receive placebo (all patients will be given PVT201).

Conditions

  • Primary Biliary Cholangitis (PBC)

Interventions

  • PVT201Drug

    Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor. PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells. IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections. PVT201 will be administered intravenously.

  • PlaceboOther

    Participants randomized to placebo will be administered normal saline IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  2. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  3. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  4. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  5. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  6. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  7. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  8. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  9. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  10. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  11. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
  12. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.